 |
| |
| Apr-17-18 | Downgrade |
Morgan Stanley |
Overweight → Equal-Weight |
|
|
| Apr-12-18 | Reiterated |
Citigroup |
Buy |
$78 → $70 |
|
| Mar-20-18 | Reiterated |
JP Morgan |
Overweight |
$70 → $75 |
|
| Feb-15-18 | Upgrade |
Morgan Stanley |
Equal-Weight → Overweight |
|
|
| Oct-30-17 | Upgrade |
SunTrust |
Hold → Buy |
|
|
| Oct-16-17 | Downgrade |
Jefferies |
Buy → Hold |
|
|
| Sep-12-17 | Downgrade |
Hilliard Lyons |
Long-term Buy → Neutral |
|
|
| Dec-19-16 | Upgrade |
Jefferies |
Hold → Buy |
|
|
| Oct-28-16 | Reiterated |
Deutsche Bank |
Hold |
$59 → $52 |
|
| Sep-09-16 | Reiterated |
Barclays |
Equal Weight |
$75 → $65 |
|
| Aug-11-16 | Downgrade |
Berenberg |
Buy → Hold |
|
|
| Aug-08-16 | Reiterated |
Deutsche Bank |
Hold |
$68 → $62 |
|
| Aug-08-16 | Downgrade |
Credit Suisse |
Outperform → Neutral |
$63 |
|
| Aug-05-16 | Downgrade |
Morgan Stanley |
Overweight → Equal-Weight |
|
|
| May-23-16 | Initiated |
Hilliard Lyons |
Neutral |
|
|
| Apr-29-16 | Reiterated |
UBS |
Buy |
$73 → $80 |
|
| Apr-29-16 | Reiterated |
Barclays |
Equal Weight |
$70 → $75 |
|
| Apr-06-16 | Initiated |
Societe Generale |
Sell |
$48 |
|
| Jan-22-16 | Upgrade |
Berenberg |
Hold → Buy |
|
|
| Dec-02-15 | Upgrade |
Guggenheim |
Neutral → Buy |
|
|
|
|
| May-21-18 07:15AM | Bristol-Myers Squibb and Three Additional Stocks Under Scanner in the Drug Makers Space ACCESSWIRE |
| May-16-18 05:07PM | Bristol-Myers Squibb Highlights Breadth of Immuno-OncologyBased Combination Research and Commitment to Advancing Precision Medicine at ASCO 2018 Business Wire |
| 07:09AM | Jim Cramer Advises His Viewers On Consolidated Edison, L Brands And More Benzinga |
| May-15-18 06:59PM | Cramer's lightning round: Take a pass on Bristol-Myers Sq... CNBC Videos |
| 06:47PM | Cramer's lightning round: Take a pass on Bristol-Myers Squibb shares for now CNBC |
| 02:28PM | Nektar Therapeutics Stock Is Risky But Offers Big Reward InvestorPlace |
| 06:59AM | Bristol-Myers Squibb to Take Part in UBS 2018 Global Healthcare Conference Business Wire |
| May-10-18 05:50PM | Big Peninsula biotech buyout means happy returns for Kleiner Perkins, other VCs American City Business Journals |
| 02:58PM | MARKETS: Biotech and pharma stocks could be the key to the market bull case Yahoo Finance Video |
| May-09-18 11:20AM | Why Bristol-Myers Squibb Stock Crashed in April Motley Fool |
| May-07-18 02:32AM | Roche's Tecentriq combo wins fast FDA review in race to catch rivals Reuters |
| May-04-18 05:35PM | As emergency blood-thinner antidote scores FDA OK, Peninsula drug maker's stock soars American City Business Journals |
| 02:14PM | Portola Pharma Rips 20% Higher After FDA Approves Andexxa Antidote Benzinga |
| 11:55AM | Q1 Earnings Drag Pharma ETFs Down Zacks |
| 08:00AM | 2 Cheap Growth Stocks to Buy Right Now Motley Fool |
| May-03-18 10:24AM | What's in Store for Celldex (CLDX) This Earnings Season? Zacks |
| 08:38AM | European Medicines Agency Validates Bristol-Myers Squibbs Type II Variation Application for Opdivo Plus Yervoy Combination for Treatment of First-Line Metastatic Non-Small Cell Lung Cancer (NSCLC) Business Wire |
| May-02-18 09:31AM | The Zacks Analyst Blog Highlights: Amazon, Bristol-Myers, Time Warner, Northrop Grumman and Honda Zacks |
| 08:30AM | Bristol-Myers Squibb and Flatiron Health Expand Collaboration with a Three-Year Agreement Business Wire |
| 07:30AM | Flatiron Health, Purchased By Roche, Signs Three-Year Deal With Bristol-Myers Forbes |
| May-01-18 04:39PM | How Bristol-Myers Squibb's new Peninsula digs boost its battle to beat cancer American City Business Journals |
| 04:11PM | Dow Jones' Merck Slides On Mixed First Quarter As Keytruda Sales Pop Investor's Business Daily |
| 03:41PM | Stephanie Link adds to Zimmer Biomet after earnings & bets on one gambling giant CNBC |
| 11:05AM | Top Stock Reports for Amazon, Bristol-Myers & Time Warner Zacks |
| 07:21AM | Sales of cancer drug Keytruda power Merck to a first-quarter earnings beat CNBC |
| Apr-30-18 04:47PM | Can These Top-Performing Biotech Stocks Keep Climbing? Motley Fool |
| Apr-27-18 03:12PM | BMO Sees Balanced Risk-Reward In Bristol-Myers, Takes Neutral Position Benzinga |
| 08:17AM | Is Bristol-Myers Squibb Stock a Buy After Its Mixed Q1 Results? Motley Fool |
| 07:00AM | Advantagene Announces Clinical Trial Collaboration GlobeNewswire |
| Apr-26-18 10:16PM | Edited Transcript of BMY earnings conference call or presentation 26-Apr-18 2:30pm GMT Thomson Reuters StreetEvents |
| 04:29PM | How AbbVie 'Crushed It' On Hepatitis C As Fellow Drugmaker Bristol Dips Investor's Business Daily |
| 12:15PM | Bristol-Myers Squibb Co Reports Earnings for First Quarter of 2018 InvestorPlace |
| 12:03PM | Bristol-Myers raises 2018 forecast, some sales disappoint Reuters |
| 11:15AM | Bristol-Myers Squibb Reports First Quarter Financial Results Business Wire |
| 10:21AM | Bristol-Myers (BMY) Beats on Q1 Earnings, Opdivo Impresses Zacks |
| 10:05AM | Drug Makers: A Dose of Robust Earnings Barrons.com |
| 09:28AM | Stocks to Watch: Facebook, Qualcomm, AT&T, Ford, GM, Chipotle, Visa, eBay, Amazon, PayPal, Southwest The Wall Street Journal |
| 09:20AM | Bristol-Myers Squibb Company to Host Earnings Call ACCESSWIRE |
| 08:28AM | How AbbVie 'Crushed It' On Hepatitis C As Fellow Drugmaker Bristol Dips Investor's Business Daily |
| 07:29AM | Bristol-Myers (BMY) Q1 Earnings Beat Estimates Zacks |
| 07:22AM | Bristol-Myers reports Q1 profit beat, revenue miss MarketWatch |
| 07:18AM | Bristol-Myers: 1Q Earnings Snapshot Associated Press |
| 07:15AM | Bristol-Myers' cancer drug Opdivo fuels growth, but revenue falls short CNBC |
| Apr-25-18 04:20PM | European Commission Approves Bristol-Myers Squibbs Opdivo (nivolumab) Four-Week Dosing Schedule for Advanced Melanoma and Previously Treated Renal Cell Carcinoma Business Wire |
| 03:07PM | Drug Maker Bristol-Myers Squibb Is Having a Bad Reaction to Selling TheStreet.com |
| 10:56AM | Drug Stock Q1 Earnings Due on Apr 26: ABBV, ALXN, BMY & VRTX Zacks |
| 08:52AM | Why Bristol-Myers (BMY) Might Surprise This Earnings Season Zacks |
| Apr-24-18 07:14PM | Cramer Remix: Navigating buying opportunities in tech amid a sell-off CNBC |
| 07:01PM | Cramer's lightning round: Wait for Take Two's earnings before buying CNBC |
| 01:14PM | Why Bristol-Myers Squibb Companys (NYSE:BMY) ROE Of 8.23% Does Not Tell The Whole Story Simply Wall St. |
| 06:00AM | Amid drug price worries, earnings to test U.S. pharma, biotech shares Reuters |
| Apr-23-18 04:36PM | Amid drug price worries, earnings to test U.S. pharma, biotech shares Reuters |
| 10:00AM | Is a Beat in Store for Bristol-Myers (BMY) in Q1 Earnings? Zacks |
| Apr-20-18 08:35PM | Aptevo executive Jane Gross jumped to a startup and landed in the C-Suite American City Business Journals |
| 10:43AM | Pharma Stock Roundup: NVS, JNJ Q1 Sales & Earnings Top, MRK & BMY Active at AACR Zacks |
| Apr-19-18 05:44PM | Bristol-Myers' Opdivo Gets Priority Review for Lung Cancer Zacks |
| 10:38AM | EARNINGS: Philip Morris misses on revenue, selling fewer cigarettes in Saudi Arabia Yahoo Finance Video |
| Apr-18-18 04:15PM | U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Patients with Small Cell Lung Cancer and Grants Priority Review Business Wire |
| 12:41PM | Trader adding to this beaten pharma stock CNBC Videos |
| 10:35AM | NEWS BITES: Barbara Bush dies at 92, Sessions proposes new limits on opioid production, tax day extended Yahoo Finance Video |
| 07:45AM | The Newest, Undiscovered CAR-T Play with a Rock-Star Partner Portfolio & Significant Near-Term Upside Potential ACCESSWIRE |
| Apr-17-18 02:29PM | Coke Versus Pepsi of Drugmakers? Wall Street Doesn't Buy It Bloomberg |
| 02:16PM | One Up, One Down: Morgan Stanley Flips Merck, Bristol-Myers Ratings Benzinga |
| 12:13PM | Calculating The Intrinsic Value Of Bristol-Myers Squibb Company (NYSE:BMY) Simply Wall St. |
| 10:52AM | Bristol-Myers (BMY) Down as Merck NSCLC Study Fares Better Zacks |
| 10:44AM | MARKETS: Wall Street's biggest fear is a trade war and FAANG+BAT is still the most crowded trade Yahoo Finance Video |
| 08:34AM | Stocks Push Forward As Fears of War Diminish InvestorPlace |
| 08:20AM | Todays Research Reports on Trending Tickers: Bristol-Myers Squibb and TESARO ACCESSWIRE |
| 06:58AM | Merck shares surge anew on lung cancer advance, while Bristol-Myers stock plummets MarketWatch |
| 06:32AM | Pfizer Reportedly Rules Out Bristol-Myers Squibb Deal -- Here Are 3 Better Acquisition Targets Motley Fool |
| 12:45AM | [$$] New Drug Combinations Improve Survival in Lung Cancer The Wall Street Journal |
| Apr-16-18 04:57PM | What Happened in the Stock Market Today Motley Fool -7.79% |
| 04:41PM | Bristol-Myers Partners With Janssen on Anticlotting Therapy Bloomberg |
| 04:32PM | The Biggest Movers: J.B. Hunt Jumps; Bristol Myers Drops Barrons.com |
| 04:26PM | Bristol Topples After Merck Treatment Outperforms It In Lung Cancer Tests Investor's Business Daily |
| 04:15PM | Bristol-Myers Squibb Announces Worldwide Collaboration with Janssen to Develop and Commercialize Next-Generation Cardiovascular Therapy Business Wire |
| 04:03PM | In CheckMate -141, Opdivo (nivolumab) Demonstrated Sustained Overall Survival (OS) Advantage over Standard of Care in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Business Wire |
| 02:09PM | Merck extends lead over Bristol-Myers in lung cancer race CNBC Videos |
| 01:33PM | Merck Expands Lead Over Bristol-Meyers in Lung Cancer Drugs Bloomberg Video |
| 01:33PM | Merck Expands Lead Over Bristol-Meyers in Lung Cancer Drugs Bloomberg |
| 01:18PM | Merck to move scientists and money toward promising cancer drug American City Business Journals |
| 12:52PM | U.S. Food and Drug Administration Approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) Combination as First-Line Treatment for Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma Business Wire |
| 12:05PM | [$$] Bristol-Myers Has Farther to Fall The Wall Street Journal |
| 11:35AM | Survival data boosts Merck's Keytruda lead in lung cancer Reuters |
| 11:17AM | Merck Notches Key Win Over Bristol-Myers on Lung Cancer Study Data TheStreet.com |
| 10:37AM | Bristol-Myers Reports Positive Data in NSCLC Trial on Opdivo Zacks |
| 10:12AM | Merck shares rise after beating rivals' lung cancer results MarketWatch |
| 09:38AM | Bristol-Myers and Merck meet cancer study goals CNBC Videos |
| 09:30AM | [$$] New Drug Combinations Improve Survival in Lung Cancer The Wall Street Journal |
| 09:30AM | Merck Keeps Edge Over Bristol-Myers In Cancer Duel Forbes |
| 09:30AM | Merck drug results suggest it will extend its lead in lung cancer; Bristol-Myers shares drop CNBC |
| 09:30AM | Merck Cements Lead in Lung Cancer With Bristol-Myers Fizzling Bloomberg |
| 09:24AM | Bristol-Myers says cancer drug combo reduces death risk Reuters |
| 09:19AM | Bristol-Myers Says Lung Cancer Drug Combination Met Trial Goal Bloomberg |
| 09:05AM | Opdivo Plus Low-Dose Yervoy Combination Reduces the Risk of Progression or Death by 42% Versus Chemotherapy in First-Line Lung Cancer Patients with High Tumor Mutational Burden (TMB) Business Wire |
| 07:10AM | Stock Market Futures Rally After Syria Mission 'Accomplished'; These 5 S&P 500 Stocks Have Big News Investor's Business Daily |
| Apr-15-18 09:30PM | [$$] Merck lung cancer trial boosts immunotherapy hopes Financial Times |
| Apr-13-18 04:51PM | Illumina shares advance on Bristol-Myers cancer drug collaboration MarketWatch |
| 04:34PM | Opdivo (nivolumab), First PD-1 Inhibitor to Demonstrate Superior Survival Benefit Compared with Chemotherapy in a Predominantly Chinese Population with Previously Treated Non-Small Cell Lung Cancer (NSCLC) Business Wire |
| 04:15PM | Bristol-Myers Squibb and Illumina Announce Strategic Collaboration to Develop and Commercialize Companion Diagnostics for Bristol-Myers Squibbs Oncology Immunotherapies Business Wire |
|
|
|
|
| Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for the treatment of anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in atrial fibrillation and the prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia. The company's products also comprise Yervoy, a monoclonal antibody for the treatment of adults and pediatric patients with unresectable or metastatic melanoma; Empliciti, a human monoclonal antibody for the treatment of multiple myeloma; Baraclude, a potent and selective inhibitor of the hepatitis B virus; Sustiva, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV and bulk efavirenz; Reyataz, a protease inhibitor for the treatment of HIV and combination therapy Evotaz; Daklinza, an oral small molecule NS5A replication complex inhibitor for the treatment of hepatitis C virus (HCV); and Sunvepra, an oral small molecule for the treatment of HCV. It sells products to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. Bristol-Myers Squibb Company has a research partnership with Sirenas; and a strategic collaboration agreement with Nektar Therapeutics, Illumina, Inc., and Janssen Pharmaceuticals, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Caforio Giovanni | Chairman and CEO | May 05 | Option Exercise | 0.00 | 8,040 | 0 | 292,822 | May 08 05:05 PM | | Paliwal Dinesh C | Director | Apr 30 | Buy | 52.40 | 4,770 | 249,948 | 8,027 | May 02 04:05 PM | | Lynch Thomas J. Jr. | EVP & Chief Scientific Officer | Apr 03 | Option Exercise | 0.00 | 12,367 | 0 | 18,267 | Apr 05 04:37 PM | | Caforio Giovanni | Chairman and CEO | Mar 10 | Option Exercise | 0.00 | 219,211 | 0 | 333,970 | Mar 13 04:56 PM | | JUDGE ANN POWELL | SVP, Global Human Resources | Mar 10 | Option Exercise | 0.00 | 36,044 | 0 | 75,370 | Mar 13 04:56 PM | | Elicker John E | SVP, Public Affairs & IR | Mar 10 | Option Exercise | 0.00 | 20,043 | 0 | 86,932 | Mar 13 04:56 PM | | Schmukler Louis S | Pres., Global Mfg. & Supply | Mar 10 | Option Exercise | 0.00 | 34,681 | 0 | 53,132 | Mar 13 04:57 PM | | Gordon Murdo | EVP, Chief Commercial Officer | Mar 10 | Option Exercise | 0.00 | 39,235 | 0 | 62,028 | Mar 13 04:55 PM | | Santiago Karen Murphy | Controller | Mar 10 | Option Exercise | 0.00 | 4,407 | 0 | 4,456 | Mar 13 04:55 PM | | Bancroft Charles A | EVP & Chief Financial Officer | Mar 10 | Option Exercise | 0.00 | 91,318 | 0 | 363,739 | Mar 13 04:53 PM | | von Autenried Paul | SVP, Enterp. Services & CIO | Mar 10 | Option Exercise | 0.00 | 31,275 | 0 | 136,441 | Mar 13 04:54 PM | | LEUNG SANDRA | EVP, General Counsel | Mar 10 | Option Exercise | 0.00 | 68,896 | 0 | 488,677 | Mar 13 04:54 PM | | Bancroft Charles A | EVP & Chief Financial Officer | Feb 23 | Option Exercise | 22.14 | 37,460 | 829,364 | 302,348 | Feb 27 04:45 PM | | Samuels Theodore R. II | Director | Dec 15 | Buy | 62.30 | 4,000 | 249,187 | 22,000 | Dec 18 04:21 PM | | Lynch Thomas J. Jr. | EVP & Chief Scientific Officer | Dec 12 | Sale | 63.24 | 5,300 | 335,172 | 9,251 | Dec 13 05:31 PM | | LEUNG SANDRA | EVP, General Counsel | Dec 04 | Option Exercise | 22.14 | 156,582 | 3,466,725 | 584,373 | Dec 05 06:15 PM | | LEUNG SANDRA | EVP, General Counsel | Dec 04 | Sale | 63.37 | 156,582 | 9,922,601 | 427,791 | Dec 05 06:15 PM | | Bancroft Charles A | EVP & Chief Financial Officer | Dec 02 | Option Exercise | 0.00 | 6,401 | 0 | 267,770 | Dec 05 06:15 PM | | Elicker John E | SVP, Public Affairs & IR | Nov 01 | Option Exercise | 0.00 | 494 | 0 | 68,166 | Nov 03 04:32 PM | | Caldarella Joseph C | SVP & Controller | Sep 06 | Sale | 60.00 | 9,340 | 560,400 | 46,297 | Sep 08 04:31 PM | | Nielsen Anne | Chief Compliance & Ethics Off | Sep 03 | Option Exercise | 0.00 | 1,594 | 0 | 38,811 | Sep 06 04:46 PM | | Samuels Theodore R. II | Director | Aug 02 | Buy | 55.94 | 6,000 | 335,622 | 18,000 | Aug 03 05:08 PM | | Gordon Murdo | EVP, Chief Commercial Officer | Aug 01 | Option Exercise | 0.00 | 1,510 | 0 | 28,751 | Aug 03 05:07 PM |
|
|
|
|
|
|
